Total Body Perfusion in Patients With Chest Pain
KOVERI
1 other identifier
observational
300
1 country
1
Brief Summary
The Purpose of this study is to better understand changes in obstructive coronary artery disease in different organs other than the heart such as the brain and the kidneys using a new generation total body PET scanner.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 11, 2023
CompletedStudy Start
First participant enrolled
April 11, 2023
CompletedFirst Posted
Study publicly available on registry
April 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2025
CompletedApril 24, 2023
April 1, 2023
2.3 years
April 11, 2023
April 11, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Perfusion in heart, brain and kidneys during rest and adenosine stress, and their associations with psychologic factors and anginal symptoms
Multiorgan perfusion changes in patients with chest pain
The imaging day
Secondary Outcomes (1)
The association between perfusion in heart, brain and kidneys, and adverse events during five year follow-up
Five year follow-up after the imaging
Eligibility Criteria
Finnish people that have history of chest pain and for which there have been done CTA which shows a possibility for obstructive coronary artery disease. All people in the study population have came to a diagnostic radiowater imgaing to know if there is significant obsturction of the coronary arteries.
You may qualify if:
- Documented history of chest pain with CT imaging showing a potential for obstructive coronary artery disease
- Ability to sustain adenosine injection 0.14 mg/kg/min
You may not qualify if:
- Second or third degree AV-block without pacemaker
- Sick sinus syndrome
- Consumption of coffee or aminophylline within 12 hours of administration
- Recent use of dipyridmole or dipyridamole-containing medications
- Known hypersensitivity to adenosine
- Unstable acute MI or acute coronary artery syndrome, and prior cardiac transplantation
- Active wheezing and bronchospasm
- Sinus bradycardia with HR\<40 bmp
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Turku University Hospital
Turku, 20520, Finland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Juhani Knuuti, MD
Turku University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 11, 2023
First Posted
April 24, 2023
Study Start
April 11, 2023
Primary Completion
August 1, 2025
Study Completion
August 1, 2025
Last Updated
April 24, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share